Second-line Hycamtin in the treatment of lung cancer.
- Author:
Yi ZHANG
1
;
Xiu-yi ZHI
;
Li-qiang ZHAO
;
Ming HAN
;
Dong-jie YAN
;
Da-ping YU
;
Jun-zhong RUAN
;
Fu-gen LI
;
Zhi-dong LIU
;
Sheng YANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antineoplastic Agents; therapeutic use; Female; Humans; Lung Neoplasms; drug therapy; mortality; Male; Middle Aged; Topotecan; adverse effects; therapeutic use
- From: Chinese Journal of Oncology 2003;25(2):193-194
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo discuss the therapeutic effect and toxicity of second line Hycamtin for lung cancer patients.
METHODSTen of these 21 patients had been treated with operation. All these 21 patients received second line Hycamtin treatment; given at the dose of 1.2 mg/m(2) per day, four consecutive days as one cycle and 21 days as one course. A total of 1 - 4 courses were given according to the patient's tolerance. Four of these 21 patients also received combination of cisplatin.
RESULTSAmong the 13 un-operated patients, two patients showed CR, six showed PR, three SD and two PD, giving an effective rate of 62%. Among the 8 operated patients, seven showed SD but one developed distant metastasis. The 1-year survival rate was 88%.
TOXICITYleukopenia I-II degree 14 (66.7%), leukopenia III-IV degree 5 (23.8%), thrombocytopenia III-IV degree 1 (4.8%) and one patient died of high fever and neutocytopenia. Nausea 8 (38.1%), vomiting 3 (14.3%) and diarrhea 2 (9.5%) alopecia 4 (19.1%). Were the other side-effects.
CONCLUSIONHycamtin is indicated for second line therapy for lung cancer giving tolerable toxicity.
